Speaking to Fierce at the European Society for Medical Oncology (ESMO) Congress in Berlin at the time, GSK’s Hesham Abdullah, ...
GSK has completed its 950 million dollar acquisition of 35Pharma, adding HS235, a promising pulmonary hypertension therapy, ...
As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the British drug giant feels prepared for any challenges that U.S. drug import ...
Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug ...
GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing ...
By Bhanvi Satija LONDON, April 12 (Reuters) - British drugmaker GSK's experimental targeted cancer drug Mo-rez has ...
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK ...
Astellas will close a stem cell therapy site. GSK is pushing a Hansoh Pharma-partnered ADC into multiple phase 3 trials. | ...
A cancer drug licensed by GSK from China has delivered promising results in a trial, in a boost for the company’s oncology ...
John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. Lizzy Lawrence leads STAT’s ...
We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results